Surface Oncology, Inc. (NasdaqGM: SURF)
Health Care · Biotechnology · US
$—
— today · — 1Y
Surface Oncology, Inc. (NasdaqGM: SURF) operates in the Biotechnology industry within the Health Care sector.
Tweenvest scores Surface Oncology, Inc. across four factors: quality 36/100, value 48/100, growth 100/100. Its strongest factor is growth.
SURF price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- —
- Revenue (TTM)
- $0.00
- P/E
- —
- EPS
- -1.53
- Dividend yield
- —
- Beta (5Y)
- —
- 52-week high
- $—
- 52-week low
- $—
- Avg volume (3M)
- —
- Shares outstanding
- —
- Employees
- 35
- Next earnings
- —
About Surface Oncology, Inc.
Surface Oncology, Inc. is a clinical-stage biotechnology firm focused on discovering and developing innovative immuno-oncology treatments for cancer patients in the United States. Its pipeline features a range of antibody-based therapeutics, including NZV930, a fully human IgG4 monoclonal antibody designed to modulate extracellular adenosine production, and SRF617, another human IgG4 monoclonal antibody that aims to block CD39's enzymatic activity, thereby influencing adenosine levels and ATP degradation. Other key candidates include SRF388, which targets interleukin 27; GSK4381562, an antibody aimed at CD112R, an inhibitory protein found on natural killer and T cells; and SRF114, which targets the chemokine receptor CCR8. The company also maintains strategic partnerships, holding a licensing agreement with GlaxoSmithKline Intellectual Property (No. 4) Limited for the development, manufacturing, and commercialization of SRF813-targeting antibodies. Furthermore, it has a separate licensing deal with Vaccinex, Inc. concerning the development, production, and commercialization of antibodies targeting SRF114. Established in 2014, Surface Oncology, Inc. operates from its headquarters in Cambridge, Massachusetts.
- ISIN
- US86877M2098
- Founded
- 2014
- Listed since
- Apr 19, 2018
- Exchange
- Nasdaq Global Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| PhaseRx, Inc.OTCPK: PZRX.Q | $12.00 | $— | — |
| ContraFect CorporationOTCPK: CFRX.Q | $11.00 | $0.00 | — |
| Notable Labs, Ltd.OTCPK: NTBL.Q | $10.00 | $— | — |
| OncoSec Medical IncorporatedOTCPK: ONCS.Q | $6.00 | $0.00 | — |
| Calithera Biosciences, Inc.OTCPK: CALA | $5.00 | $0.00 | -99.00% |
| Biocept, Inc.OTCPK: BIOC.Q | $3.00 | $0.00 | -99.50% |
| Yield10 Bioscience, Inc.OTCPK: YTEN.Q | $1.00 | $— | — |
| LadRx CorporationOTCPK: LADX | $0.00 | $0.00 | -99.50% |
Figures last refreshed Oct 18, 2026.